Article Data

  • Views 434
  • Dowloads 141

Experimental Research

Open Access

Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer

  • C. Ma1
  • L.X. Li2
  • Y. Zhang1,*,
  • C. Xiang1
  • T. Ma1
  • Z.Q. Ma1
  • Z.P. Zhang1

1Department of Oncology, the First Hospital of Shijiazhuang, Shijiazhuang, P.R. China

2Department of Clinical Laboratory, the First Hospital of Shijiazhuang, Shijiazhuang, P.R. China

DOI: 10.12892/ejgo2586.2015 Vol.36,Issue 2,April 2015 pp.192-196

Published: 10 April 2015

*Corresponding Author(s): Y. Zhang E-mail: yanzhangdoc@163.com

Abstract

Objective: This study aims to investigate the protective and sensitive effects of melatonin (MLT) in the treatment of breast cancer. Materials and Methods: ER+ breast cancer rat model was established and then rats were randomly divided into five different groups as follows: control group, Diss group, adriamycin (ADM) group, MLT group, and MLT combined with adriamycin (M+A) group. Tumor weights and one month survival rate were compared among these groups. In addition, changes of tumor tissues and expression of Ecadherin were observed under optical microscopy or electro-microscopy. Results: Tumor weights were significantly lighter in M+A group than those in ADM group (p < 0.05). Under optical and electro-microscopy, tumor cell apoptosis was obviously increased in MLT group, and tumor cell injury was more severe in M+A group than that in ADM group; additionally, expression of E-cadherin was higher in MLT group and M+A group than that in other groups. Moreover, MLT group had the highest one month survival rate (100%), there was the poorest life quality in ADM group, but the best life quality in MLT. Conclusion: MLT could enhance the sensitivity of tumor to ADM in vivo and improve patient’s life quality.

Keywords

Melatonin; Breast cancer; Adriamycin; Metastasis.

Cite and Share

C. Ma,L.X. Li,Y. Zhang,C. Xiang,T. Ma,Z.Q. Ma,Z.P. Zhang. Protective and sensitive effects of melatonin combined with adriamycin on ER+ (estrogen receptor) breast cancer. European Journal of Gynaecological Oncology. 2015. 36(2);192-196.

References

[1] Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R.: “Anthracycline cardiomyopathy monitored by morphologic changes”. Cancer Treat. Rep., 1978, 62, 865.

[2] Bristow M.R., Thompson P.D., Martin R.P., Mason J.W. Billingham M.E., Harrison D.C.: “Early anthracycline cardiotoxicity”. Am. J. Med., 1978, 65, 823.

[3] Rock E., DeMichele A.: “Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors”. J. Nutr., 2003, 133, 3785S.

[4] Chicco A.J., Schneider C.M., Hayward R.: “Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart”. Am. J. Physiol. Regul. Integ.r Comp. Physiol., 2005, 289, R424.

[5] Chicco A.J., Schneider C.M., Hayward R.: “Exercise training attenuates acute doxorubicin-induced cardiac dysfunction”. J. Cardiovasc. Pharmacol., 2006, 47, 182.

[6] Hydock D.S., Lien C.Y., Schneider C.M., Hayward R.: “Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction”. Med. Sci. Sports Exerc., 2008, 40, 808.

[7] Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M.: “Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention”. J. Natl. Cancer. Inst., 2010, 102, 14.

[8] Sánchez-Barceló E.J., Cos S., Mediavilla D., Martínez-Campa C., González A., Alonso-González C.: “Melatonin-estrogen interactions in breast cancer”. J. Pineal Res., 2005, 38, 217.

[9] Jawed S., Kim B., Ottenhof T., Brown G.M., Werstiuk E.S., Niles L.P.: “Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation”. Eur. J. Pharmacol., 2007, 560, 17.

[10] Lissoni P.: “Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent”. Pathol. Biol., 2007, 55, 198.

[11] Martínez-Campa C., González A., Mediavilla M.D., Alonso-González C., Alvarez-García V., Sánchez-Barceló E.J., et al.: “Melatonin inhibits aromatase promoter expression by regulating clooxygenases expression and activity in breast cancer cells”. Br. J. Cancer., 2009, 101, 1613.

[12] Zhang Y., Zhu S., Liu J.: “The reverse effect and mechanism of melatonin on breast carcinoma cell line MCF-7/ADM resistant to Adriamycin”. Chinese Journal of Clinical Oncology, 2009, 36, 291.

[13] Zhang Y., Zhu S., Zhao W.: “The effect of melatonin on the sensitivity of ER+ breast carcinoma cell line MCF-7 to Adriamycin and its mechanism”. Chinese Journal of Clinical Oncology, 2009, 36, 1243.

[14] Orendas P., Kassayova M., Kajo K., Ahlers I., Kubatka P., Bojkova B., et al.: “Celecoxib and melatonin in prevention of female rat mammary carcinogenesis”. Neoplasma, 2009, 56, 252.

[15] Wei W., Shen Y.X., Dai M., Chen Q.: “Effects and mechanisms of melatonin on immune responses in mice of different months”. Acta Pharmacol. Sin., 2003, 24, 719.

[16] Esquifinoa A.I., Pandi-Perumalb S.R., Cardinali D.P.: “Circadian organization of the immune response: A role for melatonin”. Clinical and Applied Immunology Reviews, 2004, 4, 423.

[17] Leon-Blanco M.M., Guerrero J.M., Reiter R.J., Pozo D.: “RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line”. Cancer Lett., 2004, 216, 73.

[18] Mirunalini S., Karthishwaran K., Dhamodharan G., Shalini M.: “Melatonin attenuates lipid peroxidation and enhances circulatory antioxidants during mammary carcinogenesis in rats”. J. Biochem. Tech., 2010, 2, 171.

[19] Lissoni P.: “Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms”. Pathologie Biologie, 2007, 55, 201.

[20] Miller S.C., Pandi P.S., Esquifino A.I., Cardinali D.P., Maestroni G.J.: “The role of melatonin in immounoenhancement: potential application in cancer”. Int. J. Exp. Pathol., 2006, 87, 81.

[21] Srinivasn V., Spence D.W., Pandi-Perumal S.R.: “Therapeutic actions of melatonin in cancer: possible mechanisms”. Integr. Cancer Ther., 2008, 7, 189.

[22] Bruck R., Aeed H., Avni Y., Shirin H., Matas Z., Shahmurov M., et al.: “Melatonin inhibits nuclear factor kappa B activation and oxidativestress and protects against thioacetamide induced liver damage in rats”. J. Hepatol., 2004, 40, 86.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top